DDInter810 DDInter1435
Gefitinib (originally coded ZD1839) is a drug used in the treatment of certain types of cancer. Acting in a similar manner to erlotinib (marketed as Tarceva), gefitinib selectively targets the mutant proteins in malignant cells. It is marketed by AstraZeneca under the trade name Iressa.
Pexidartinib is a selective tyrosine kinase inhibitor that works by inhibiting the colony-stimulating factor (CSF1)/CSF1 receptor pathway. Pexidartinib was originally developed by Daiichi Sankyo, Inc. and it was approved by the FDA in August 2019 as the first systemic therapy for adult patients with symptomatic tenosynovial giant cell tumor. Tenosynovial giant cell tumor is a rare form of non-malignant tumor that causes the synovium and tendon sheaths to thicken and overgrow, leading to damage in surrounding joint tissue.[A182240,L7901] Debilitating symptoms often follow with tenosynovial giant cell tumors, along with a risk of significant functional limitations and a reduced quality of life in patients. While surgical resection is a current standard of care for tenosynovial giant cell tumor, there are tumor types where surgeries are deemed clinically ineffective with a high risk of lifetime recurrence. Pexidartinib works by blocking the immune responses that are activated in tenosynovial giant cell tumors. In clinical trials, pexidartinib was shown to promote improvements in patient symptoms and functional outcomes in TGCT. Pexidartinib is available in oral formulations and it is commonly marketed as Turalio.
Gefitinib {u} (Compound) resembles {v} (Compound) Bosutinib
Gefitinib {u} (Compound) resembles {v} (Compound) Erlotinib
Gefitinib {u} (Compound) treats {v} (Disease) lung cancer
Gefitinib {u} (Compound) binds {v} (Gene) CYP2D6
Gefitinib {u} (Compound) upregulates {v} (Gene) ZNF589
Gefitinib {u} (Compound) downregulates {v} (Gene) IFRD2
Gefitinib {u} (Compound) causes {v} (Side Effect) Appetite absent
Gefitinib {u} may cause a minor interaction that can limit clinical effects when taken with {v} Modafinil
Gefitinib {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Danazol
Gefitinib {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Bexarotene
Gefitinib (Compound) resembles Bosutinib (Compound)
Gefitinib (Compound) resembles Erlotinib (Compound)
Gefitinib (Compound) treats lung cancer (Disease)
Gefitinib (Compound) binds CYP2D6 (Gene)
Gefitinib (Compound) upregulates ZNF589 (Gene)
Gefitinib (Compound) downregulates IFRD2 (Gene)
Gefitinib (Compound) causes Appetite absent (Side Effect)
Gefitinib may cause a minor interaction that can limit clinical effects when taken with Modafinil
Gefitinib may cause a moderate interaction that could exacerbate diseases when taken with Danazol
Gefitinib may cause a moderate interaction that could exacerbate diseases when taken with Bexarotene